NCT02695992View on ClinicalTrials.gov

Rate Control in Atrial Fibrillation II

PHASE4CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

October 31, 2021

Study Completion Date

November 12, 2021

Conditions
Atrial FibrillationPermanent Atrial Fibrillation
Interventions
DRUG

Metoprolol

Dosage 100 mg o.d.

DRUG

Diltiazem

Dosage 360 mg o.d.

Trial Locations (1)

1309

Vestre Viken Hospital Trust, Baerum Hospital, Rud

All Listed Sponsors
collaborator

Vestre Viken Hospital Trust

OTHER

collaborator

Helse Sor-Ost

OTHER_GOV

lead

Asker & Baerum Hospital

OTHER

NCT02695992 - Rate Control in Atrial Fibrillation II | Biotech Hunter | Biotech Hunter